| If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| | | ![]() DG DISPATCH - AACAP: Paroxetine Ineffective For Adolescent Unipolar Depression By Lara Pullen Special to DG news CHICAGO, IL -- October 22, 1999 -- While depression in adults has been well-studied, adolescent depression and the optimal pharmacotherapy for this age group is not as well understood. A recent study addresses this data gap with evidence that paroxetine, a selective serotonin reuptake inhibitor (SSRI), is not an effective treatment for adolescent unipolar depression.
Dr. Robert P. Milin, of Royal Ottawa Hospital, in Ottawa, ON, presented the results of an international, placebo-controlled, clinical trial yesterday (Oct. 21) at the 46th annual meeting of the American Academy of Child and Adolescent Psychiatry (AACAP). The objective of the study was to assess the efficacy and safety of paroxetine in the treatment of adolescents with unipolar major depression. The studied consisted of 286 patients aged 13 to 18 years who were randomized to receive paroxetine (20-40 mg daily) or placebo for 12 weeks. No statistically significant differences were detected between the two groups. The data did suggest, however, that adolescents over the age of 16 might respond positively to paroxetine treatment. While the study results are generally negative, Dr. Milin believes that it is important that even negative findings be reported. These results are especially critical during the investigative stages of pharmacological trials as they add to the understanding and optimization of drug therapies. "We all know that medications work for certain kids… The question is how do you go about prescribing them," Dr. Milin explained.
|